Infusion of PD1/PDL1 Inhibitor Via Neck Artery Versus Vein for Immunotherapy of Head/Neck Cancers (HNC)
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This trial was designed to investigate the survival outcomes, response rates, and safety of
patients with advanced Head/Neck Squamous cancer by neck artery versus vein infusion of
PD1/PDL1 inhibitor.
Phase:
Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University